These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26684860)

  • 1. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
    Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
    Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
    Rustagi S; Warner RR; Divino CM
    J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
    Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
    Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
    Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
    QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.
    O'Dorisio TM; Krutzik SR; Woltering EA; Lindholm E; Joseph S; Gandolfi AE; Wang YZ; Boudreaux JP; Vinik AI; Go VL; Howe JR; Halfdanarson T; O'Dorisio MS; Mamikunian G
    Pancreas; 2010 Jul; 39(5):611-6. PubMed ID: 20124939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors.
    Edfeldt K; Daskalakis K; Bäcklin C; Norlén O; Tiensuu Janson E; Westin G; Hellman P; Stålberg P
    Neuroendocrinology; 2017; 105(2):170-181. PubMed ID: 27829249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
    Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW
    Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreastatin predicts survival in neuroendocrine tumors.
    Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.
    Strosberg D; Schneider EB; Onesti J; Saunders N; Konda B; Shah M; Dillhoff M; Schmidt CR; Shirley LA
    Ann Surg Oncol; 2018 Nov; 25(12):3613-3620. PubMed ID: 30182331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel.
    Woltering EA; Voros BA; Beyer DT; Thiagarajan R; Ramirez RA; Mamikunian G; Boudreaux JP
    Pancreas; 2019 Mar; 48(3):356-362. PubMed ID: 30768573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
    Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
    Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis.
    Ardill JE; McCance DR; Stronge WV; Johnston BT
    Ann Clin Biochem; 2016 Mar; 53(Pt 2):259-64. PubMed ID: 26038607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
    Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
    PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis.
    Fata CR; Gonzalez RS; Liu E; Cates JM; Shi C
    Am J Surg Pathol; 2017 Jan; 41(1):128-133. PubMed ID: 27684993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum.
    Woltering EA; Beyer DT; Thiagarajan R; Ramirez RA; Wang YZ; Ricks MJ; Boudreaux JP
    J Am Coll Surg; 2016 Apr; 222(4):534-42. PubMed ID: 26827125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    J Am Coll Surg; 2010 Nov; 211(5):620-7. PubMed ID: 21035044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.